Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34+ cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine
Annals of Hematology, 05/17/2012
Wu L et al. – The over–expression of RPL23 might confer apoptosis resistance in CD34+ cells, which may lead to disease progression and adverse prognosis in myelodysplastic syndrome (MDS). Increased RPL23 expression was an inverse indicator for CHG regimen, but not for decitabine treatment.
